Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Juergen Rockstroh, Nina Weis, George J. Hanna(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex Lund Laursen(Aarhus University), Alexander Zoufaly(Kaiser-Franz-Josef-Spital), Anthony Rodgers(The George Institute for Global Health), Christine Katlama(Université Paris Cité), Sushma Kumar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Norma Porteiro, Johan Lombaard, Xia Xu(Pfizer (United States)), Carolina Eugenia Chahin, Alejandro Afani, Carey Hwang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard James Moore, Mark Bloch(Epworth Hospital), Robert Finlayson, Lisa Lupinacci(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pedro Cahn(Hospital San Juan de Dios), Gustavo Lopardo, Yazdan Yazdanpanah(Inserm), Graham Smith, Sylvia Hartl, Armin Rieger, Maria Isabel Enriqueta Campos Barker, Carlos Enrique Tene Pérez, James McMahon, Ming‐Tain Lai(Leo Pharma (Australia)), Edwin DeJesus(Orlando Immunology Center), David Alfred Baker, Jan Gerstoft, Francois Raffi, Philippe Morlat, Anita Rachlis(University of Toronto), Brian Conway, Norman Roth, Robert Zangerle, Fiona Smaill, Marcelo Martins, Laurent Cotte(San Francisco General Hospital), Bach‐Yen Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pierre-Marie Girard, Paul E. Sax(Brigham and Women's Hospital), Kathleen Squires(Thomas Jefferson University), Sharon Walmsley(University Health Network)
The Lancet HIV
March 25, 2018
Cited by 145


Related Papers